{"entity":{"id":"paper-reyburn-single-dose-hpv-fiji-lanwpc-2023","kind":"paper","name":"A single dose of quadrivalent HPV vaccine is highly effective against HPV genotypes 16 and 18 detection in young pregnant women eight years following vaccination: an retrospective cohort study in Fiji","aka":[],"tldr":"Eight years after Fiji's 2008 and 2009 HPV vaccination campaign, a single dose of the quadrivalent vaccine was 81% effective against HPV 16 and 18 in 822 young pregnant women.","summary":"In 2008 and 2009 Fiji vaccinated more than 30,000 girls aged 9 to 12 with the quadrivalent HPV vaccine; coverage for at least one dose was over 60%, with 14% receiving one dose only, 13% two and 35% three. This retrospective cohort study, run from 2015 to 2019, enrolled pregnant women aged 23 or under who had been eligible for the vaccine and whose vaccination status was confirmed, a median of eight years after vaccination. It was funded by the Bill and Melinda Gates Foundation and the Australian Government.","asOf":"2026-11-16","links":[{"label":"DOI","url":"https://doi.org/10.1016/j.lanwpc.2023.100798"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/37359996/"}],"tags":[],"related":[],"cancers":["cervical"],"sections":[],"technologies":["hpv-vaccine"],"targets":[],"drugs":[],"companies":[],"institutions":["fiji-ministry-of-health"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"journal":"The Lancet Regional Health. Western Pacific","year":2023,"doi":"10.1016/j.lanwpc.2023.100798","pmid":"37359996","authors":"Reyburn R, Tuivaga E, Ratu T, et al.","paperType":"observational","findings":["HPV 16 or 18 was detected in 13.3% (50 of 376) of unvaccinated women, 2.5% (4 of 158) after one dose, 0% (0 of 99) after two and 1.6% (3 of 189) after three.","Adjusted vaccine effectiveness against HPV 16 and 18 was 81% for one dose (95% CI 48 to 93), 100% for two and 89% for three (95% CI 64 to 96).","Detection of non-vaccine high-risk types was similar across the groups (33.2% to 40.4%)."],"whatItMeans":"One dose of HPV vaccine gave lasting protection against the two types that cause most cervical cancers, in a Pacific island setting.","caveats":["Restricted to pregnant women, because of the cultural sensitivity of asking about sexual behaviour in Fiji.","Retrospective, and it measured HPV infection, not cervical disease."],"participants":822},"route":"/key-papers/paper-reyburn-single-dose-hpv-fiji-lanwpc-2023/","neighbours":{"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"}],"technology":[{"id":"hpv-vaccine","kind":"technology","name":"HPV & HBV vaccination","route":"/technologies/hpv-vaccine/"}],"institution":[{"id":"fiji-ministry-of-health","kind":"institution","name":"Ministry of Health and Medical Services, Fiji","route":"/institutions/fiji-ministry-of-health/"}]}}